יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Enochian BioSciences (RENB)

The price trajectory of Renovaro Inc. (RENB) reflects an EV/EBITDA multiple of . Renovaro Inc. is developing AI technologies and cellular analysis to combat tumors and viruses, thereby reducing reliance on a single business line. However, a high burn rate and uncertainty regarding regulatory verdicts create significant investment risks. Meanwhile, an established reagent storage system eliminates any disruptions in the conduct of current research.

This ratio determines the business value inclusive of net debt relative to operating profit, allowing investors to identify undervalued assets beyond market noise. By analyzing fluctuations in the EV/EBITDA level of Renovaro Inc. (RENB), one can assess the efficiency of the capital structure, where the optimization of chemical compound logistics for oncology research should convert into operating income growth and a reduction of the final multiple.